

July 14, 2015



## CymaBay Announces Proposed Public Offering of Common Stock

NEWARK, CA -- (Marketwired) -- 07/14/15 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. CymaBay also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallocments, if any. CymaBay anticipates using the net proceeds from the offering for general corporate purposes, including clinical trials, research and development, capital expenditures and working capital.

Piper Jaffray & Co. is acting as the sole book-running manager for the offering, and LifeSci Capital LLC is acting as the lead manager.

The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's EDGAR Filings Website: <http://www.sec.gov/>. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Piper Jaffray at 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, or by calling 800-747-3924, or by emailing [prospectus@pjc.com](mailto:prospectus@pjc.com), or LifeSci Capital LLC at 250 West 55<sup>th</sup> Street, Suite 16B, New York, NY 10019, or by calling (646) 597-6987, or by emailing [prospectus@lifescicapital.com](mailto:prospectus@lifescicapital.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:  
Sujal Shah  
CymaBay Therapeutics, Inc.  
(510) 293-8800  
[investors@cymabay.com](mailto:investors@cymabay.com)

Source: CymaBay Therapeutics